Loading
journalsJournal
Breast cancer research and treatment
Breast Cancer Research and Treatment is a long-established Springer journal spanning breast cancer biology, epidemiology and clinical management, read by breast oncologists and researchers.
Also called: Breast Cancer Research and TreatmentBreast Cancer Res Treat
Overview
Breast Cancer Research and Treatment has been published since 1981, first by Kluwer Academic in Dordrecht, the Netherlands, and now by Springer, which Crossref lists as the publisher. As its title indicates, it spans both breast cancer research and treatment, and it is one of the longest-running journals devoted to the disease. The NLM record lists it as a Netherlands serial that is indexed in MEDLINE; it is not listed in DOAJ.
rct2019343 citations
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
A second publication from the PALOMA-2 trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
observational201559 citations
The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer
A recurrent-mutation panel catches most carriers in Mexican TNBC at a fraction of the cost of full sequencing, and the large-rearrangement founder allele is missed by sequencing-only assays that do not test for deletions.
observational2014144 citations
Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing
The registry showed that age and family-history filters leak carriers, the argument that carried testing criteria from 'under 60' towards every TNBC diagnosis.
observational201161 citations
A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas
Founder-mutation screening of every breast cancer patient is justified in the Bahamas, and the finding explains part of the early-onset, BRCA1-driven triple-negative burden across Afro-Caribbean populations.
Andrew Wardley
Consultant Medical Oncologist, The Christie; Honorary Professor, University of Manchester
Breast cancerHER2-positive diseaseAdjuvant trials
Andrew Wardley is a breast oncologist involved in the PERSEPHONE trial of shorter trastuzumab.
Daniel Serin
Representative of Institut Sainte Catherine to the Organisation of European Cancer Institutes
Cancer centre representation (OECI)
Daniel Serin represents Institut Sainte Catherine in the Organisation of European Cancer Institutes, which lists the organisation among its members in France.
David Fennelly
Clinical Director for Cancer Services, St Vincent's University Hospital and St Vincent's UCD Cancer Centre
Medical oncologyCancer services leadershipNational cancer strategy
Medical oncologist who is Clinical Director for Cancer Services at St Vincent's University Hospital and its UCD Cancer Centre in Dublin, Ireland's largest cancer care provider.
Dorraya El-Ashry
Chief Scientific Officer
Breast cancer biologyTumour microenvironmentResearch strategy
Breast cancer biologist and Chief Scientific Officer of the Breast Cancer Research Foundation, directing its global research grant portfolio.
Eitan Friedman
Oncogeneticist, Meirav High Risk Clinic, Sheba Medical Center; professor, Gray Faculty of Medical and Health Sciences, Tel Aviv University
Cancer geneticsBRCA founder variantsNon-Ashkenazi Jewish and Arab cancer genetics
Mapped which inherited cancer variants recur in which Israeli communities, and showed that outside the Ashkenazi founder panel there is no shortcut: you have to sequence.
Lori J. Pierce
Professor of Radiation Oncology and Vice Provost, University of Michigan; NRG Oncology investigator; ASCO Past President (2020-2021)
Breast radiotherapyHealth equityRadiation oncology
Lori Pierce is a breast radiation oncologist and ASCO past president focused on equity in cancer care.
Rebecca Dent
Deputy Chief Executive Officer (Clinical)
Breast cancerTriple-negative breast cancerClinical trials
Breast medical oncologist and Deputy CEO for clinical operations at the National Cancer Centre Singapore, an international leader in triple-negative breast cancer trials.
Satu Tiainen
Ylilääkäri and Johtaja (Chief Physician and Director), Itäinen syöpäkeskus (FICAN East), Kuopio University Hospital
OncologyCancer centre managementRegional cancer networks
Chief physician who directs Itäinen syöpäkeskus, the FICAN East regional cancer centre hosted by Kuopio University Hospital and the Pohjois-Savo wellbeing services county.
Shinji Ohno
Director, Breast Oncology Center, Cancer Institute Hospital of JFCR
Breast cancerAdjuvant therapyClinical trials
A senior breast cancer specialist who has led Japanese arms of adjuvant and metastatic breast cancer trials for two decades.
rctBreast cancer research and treatment 2019343 citations
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
A second publication from the PALOMA-2 trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
observationalBreast Cancer Research and Treatment 201559 citations
The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer
A recurrent-mutation panel catches most carriers in Mexican TNBC at a fraction of the cost of full sequencing, and the large-rearrangement founder allele is missed by sequencing-only assays that do not test for deletions.
observationalBreast Cancer Research and Treatment 2014144 citations
Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing
The registry showed that age and family-history filters leak carriers, the argument that carried testing criteria from 'under 60' towards every TNBC diagnosis.
observationalBreast Cancer Research and Treatment 201161 citations
A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas
Founder-mutation screening of every breast cancer patient is justified in the Bahamas, and the finding explains part of the early-onset, BRCA1-driven triple-negative burden across Afro-Caribbean populations.
Similar pages
- JournalThe breast journal
Shares Ductal carcinoma in situ (DCIS), Male breast cancer, PubMed & Europe PMC, HER2-positive breast cancer.
- JournalBreast cancer
Shares Ductal carcinoma in situ (DCIS), Male breast cancer, PubMed & Europe PMC, HER2-positive breast cancer.
- JournalThe Breast
Shares Ductal carcinoma in situ (DCIS), Male breast cancer, PubMed & Europe PMC, HER2-positive breast cancer.
- JournalClinical breast cancer
Shares Ductal carcinoma in situ (DCIS), Male breast cancer, PubMed & Europe PMC, HER2-positive breast cancer.
- JournalJournal of mammary gland biology and neoplasia
Shares Ductal carcinoma in situ (DCIS), PubMed & Europe PMC, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- JournalBreast cancer research
Shares Ductal carcinoma in situ (DCIS), Male breast cancer, PubMed & Europe PMC, HER2-positive breast cancer.
- JournalJournal of breast imaging
Shares Ductal carcinoma in situ (DCIS), PubMed & Europe PMC, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- TrialPALOMA-2
Shares Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up, HR-positive / HER2-negative breast cancer.
cancers
collections
people
key papers
A high prevalence of BRCA1 mutations among breast cancer patients from the BahamasGermline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testingPalbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-upThe prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer